Document allowing an applicant to reference a DMF without direct access to the closed part.

DMF Holder: The entity responsible for preparing, maintaining, and updating both open and closed parts.

Applicant: Finished dosage form manufacturer referencing the DMF in regulatory submissions.

These definitions highlight the dual function of DMFs: enabling regulatory review while maintaining commercial confidentiality.

Applicable Guidelines and Regulatory Frameworks

Global regulatory frameworks for open and closed DMF parts include:

• FDA 21 CFR 314.420: Defines requirements for DMF submission in the US.
• EMA/EDQM CEP Guidelines: Permit confidential submissions while ensuring compliance with Ph. Eur. monographs.
• CDSCO NDCTR 2019: Requires Indian DMFs to maintain clear separation of open and closed parts.
• ICH Q7: GMP standards governing the API manufacturing process described in the closed part.
• WHO Guidance on Transparency: Encourages harmonization in managing confidential regulatory information.

These frameworks emphasize the importance of accurate and well-structured open and closed parts to meet compliance expectations worldwide.

Processes, Workflow, and Preparation Strategy

Preparing open and closed parts of a DMF involves a structured approach:

1. Content Identification: Segregate confidential manufacturing details into the closed part and shareable specifications into the open part.
2. Dossier Compilation: Structure documentation in CTD/eCTD format, ensuring Module 3 (Quality) reflects separation of parts.
3. Regulatory Submission: File the complete DMF to authorities while providing only the open part to applicants.
4. LOA Issuance: Provide applicants with authorization to reference the DMF during their NDA/ANDA/MAA submissions.
5. Ongoing Updates: Maintain both open and closed parts with annual updates and regulatory responses.

This workflow ensures regulators have full visibility into API quality while applicants access only essential, non-confidential data.

Sample Case Study: FDA Open and Closed Part Separation

Case: An Indian API manufacturer filed a Type II DMF with both open and closed parts in 2021.

• Challenge: FDA raised concerns about incomplete impurity specifications in the open part.
• Action: Holder revised the open part with expanded analytical data while safeguarding process details in the closed part.
• Outcome: DMF accepted, enabling multiple ANDA approvals.
• Lesson Learned: Clear delineation of impurity control data prevents regulatory queries.

Sample Case Study: EMA CEP Alignment

Case: A European manufacturer aligned its DMF open/closed structure with CEP requirements in 2022.

• Challenge: EDQM requested more transparency on residual solvents in the open part.
• Action: Sponsor provided analytical testing results while retaining process steps in the closed part.
• Outcome: CEP granted without delays.
• Lesson Learned: Striking the right balance of transparency ensures smoother approvals.

Sample Case Study: CDSCO DMF Filing

Case: An Indian API exporter submitted a Type I DMF with poorly separated open/closed sections in 2020.

• Challenge: CDSCO raised multiple queries on GMP compliance and facility data.
• Action: Holder restructured DMF to clearly separate open and closed parts with updated GMP certifications.
• Outcome: DMF accepted within 8 months.
• Lesson Learned: Proper structuring of DMFs reduces CDSCO queries and delays.

Tools, Software, or Templates Used

Preparing open and closed DMF parts can be streamlined with the following tools:

• eCTD Publishing Software: Lorenz, Extedo, Ennov for Module 3 preparation.
• Confidentiality Templates: Standardized formats ensuring clear separation of parts.
• Regulatory Tracking Systems: Monitor updates, LOAs, and deficiency letters.
• QMS Integration: Ensures alignment between change control and DMF updates.
• Audit-Ready Documentation: Tools for ensuring inspection readiness of both open and closed data.

These tools improve efficiency and minimize risks of exposing proprietary information.

Common Challenges and Best Practices

RA professionals managing DMFs face several challenges:

• Over-Disclosure: Accidentally including confidential data in the open part.
• Under-Disclosure: Insufficient data in the open part leading to regulatory queries.
• Misalignment: Differences in open/closed part structures across global submissions.
• Lifecycle Updates: Maintaining synchronization of updates across both parts.

Best practices include creating predefined templates, conducting internal audits before submission, aligning open/closed structures with global requirements, and ensuring applicants receive sufficient but non-sensitive data. Collaboration between RA, QA, and manufacturing teams is crucial.

Latest Updates and Strategic Insights

By 2025, DMF part preparation is influenced by global trends:

• Digital Submissions: eCTD v4.0 mandates clearer separation of open and closed sections.
• Global Harmonization: FDA, EMA, and CDSCO adopting consistent expectations for DMF structure.
• Confidentiality Protocols: Enhanced safeguards for proprietary API processes.
• AI-Assisted Structuring: Tools emerging to classify and redact confidential data automatically.
• Transparency vs Protection: Regulators balancing the need for open disclosure with confidentiality rights.

Strategically, RA professionals should view open and closed part preparation as both a compliance requirement and a competitive differentiator for global market entry.

Conclusion

Open and closed part preparation in DMFs is fundamental to balancing regulatory transparency and protection of proprietary data. By adopting structured workflows, leveraging modern tools, and applying best practices, RA professionals can ensure compliance and safeguard intellectual property. In 2025 and beyond, effective DMF structuring will remain a critical capability for global API manufacturers and regulatory teams.